Table 4 Treatment-related adverse events (TRAEs)
Treatment-related adverse events | n (%) | |
|---|---|---|
Any grade | ≥grade 2 | |
All TRAEs | 31 (53%) | 18 (31%) |
 Common TRAEs | 25 (43%) | 10 (17%) |
  Anorexia | 9 (16%) | 3 (5%) |
  Malaise | 6 (10%) | 0 |
  Nausea | 3 (5%) | 0 |
  Upper gastrointestinal hemorrhage | 2 (3%) | 2 (3%) |
  Fever | 2 (3%) | 0 |
  Localized edema | 2 (3%) | 0 |
  Creatinine increased | 2 (3%) | 0 |
  Dysgeusia | 2 (3%) | 0 |
  Pruritus | 2 (3%) | 0 |
  Nail change | 2 (3%) | 0 |
  Anemia | 1 (2%) | 1 (2%) |
  Palpitations | 1 (2%) | 1 (2%) |
  Colonic perforation | 1 (2%) | 1 (2%) |
  Neutrophil count decreased | 1 (2%) | 1 (2%) |
  Dyspnea | 1 (2%) | 1 (2%) |
  Pleural effusion | 1 (2%) | 1 (2%) |
  Eosinophilia | 1 (2%) | 0 |
  Constipation | 1 (2%) | 0 |
  Platelet count decreased | 1 (2%) | 0 |
  Proteinuria | 1 (2%) | 0 |
  Cough | 1 (2%) | 0 |
 Immune-related adverse events (irAEs) | 20 (35%) | 10 (17%) |
  Liver enzyme elevation | 7 (12%) | 3 (5%) |
  Peripheral sensory neuropathy | 4 (7%) | 2 (3%) |
  Rash maculopapular | 4 (7%) | 1 (2%) |
  Colitis | 4 (7%) | 0 |
  Hypothyroidism | 2 (3%) | 2 (3%) |
  Hyperglycemia | 1 (2%) | 1 (2%) |
  Esophagitis | 1 (2%) | 1 (2%) |
  Hypopituitarism | 1 (2%) | 1 (2%) |